الفهرس 
Immuno-modulatory effects of CTXOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
DCs have been extensively used in tumor immunotherapy in preclinical studies which resulted in several clinical trials with the goal to elicit or amplify immune responses against cancer and chronicinfectious diseases. Although a remarkable amount of data has been obtained from these studies, defining approaches that can further augment this cell-based therapy is required The present study aimed to compare microscopic investigation and phenotypic characteristics between dendritic cells from naïve and tumor bearing mice in vitro, also to determine the anti-tumor efficacy of combination cyclophosphamide (CTX)chemotherapy with dendritic cells generated from naïve or tumor bearing mice with or without tumor lysate in vivo, in addition to investigate the post vaccination cellularity, phenotypic characteristics of spleen, bone marrow and peripheral blood mononuclear cells. Furthermore, to investigate their capability to restore leucopenia-associated chemotherapy.